TL;DR
Findings from a proof-of-concept, expanded access trial for COVID-19 patients prove the acellular biologic is safe and potentiallyective to prevent disease progression in a high-risk COVID-19 population with mild-to-moderate symptoms.
Clinical data, although limited, provide evidence that the modulation of glutathione levels could be a preventive or adjunctive therapeutic strategy against SARS-CoV-2 infection.
The current guidelines for treating acute COVID-19 are outlined, information on the mechanistic rationale behind various published and ongoing clinical trials investigating potential long COVID therapeutic agents are summarized and information on the mechanistic rationale behind various published and ongoing clinical t...
Abstract The COVID-19 disease, presenting with complex immune dysregulation and leading to life-threatening organ dysfunction, represents a paradigm of viral sepsis. As heterogeneity of clinical presentation is contained in COVID-19 (one pathogen, one source of infection) related to bacterial sepsis, and due to the urg...
This study consists of an integrative literature review with an electronic search in the PubMed database, aiming to gather information and data established by the scientific community regarding the pathogenesis and development of neuropsychiatric sequelae in Post-COVID-19 Syndrome.
Translational virology encompasses all stages from basic research through clinical evaluation and final registration and drug/vaccine approval, and vaccine re-engineering has been required as part of translational virology due to emerging SARS-CoV-2 variants.
Among the complications, joint disorders occupy a special place, being recorded in 10–20% of patients, and the development of polymorbidity in such patients is closely associated with systemic vascular pathology.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
